Covid19

Adamis' shares nosedive as sole clinical-stage asset flunks COVID-19 trial – Fierce Biotech

Another COVID-19 therapy bites the dust. This time it's Adamis Pharmaceuticals' failed phase 2/3 trial for antiviral Tempol.

Read more at www.fiercebiotech.com

Show More

Related Articles

Back to top button